Human African Trypanosomiasis (HAT) Platform
Founded: 2005, Kinshasa, Democratic Republic of the Congo
120 members, from over 20 institutions
The HAT Platform builds and strengthens treatment methodologies and clinical trial capacity in sleeping sickness-endemic countries, so that new treatments for this fatal disease can be rapidly and effectively evaluated, registered, and made available to patients. After the success of the Nifurtimox-Eflornithine Combination Therapy (NECT), included in the WHO List of Essential Medicines for the treatment of stage 2 HAT, the primary goals of the HAT Platform are to develop appropriate clinical trial methodologies for sleeping sickness, overcome system challenges related to administrative and regulatory requirements, strengthen clinical trial capacity (human resources, infrastructure, equipment), and share information and strengthen ties among endemic countries.
Tawaba Say Watson, Head Nurse, Bagata, Kwilu province, Democratic Republic of the Congo
The training in good clinical practice and the site initiation of the clinical study, help me on a daily basis to improve the way we take care of all patients.
- Capacity development to facilitate access to fexinidazole
- Fexinidazole for T.b. rhodesiense
- Fexinidazole for T.b. gambiense